TY  - CONF

T1  - Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)

JO  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

PY  - 2022/01/01

AU  - Weidinger S

AU  - Bieber T

AU  - Cork M

AU  - Reich A

AU  - Gilbert S

AU  - Brennan N

AU  - Quaratino S

AU  - Wilson R

AU  - Porter-Brown B

ED  - 

VL  - 87

IS  - 3

SP  - AB206

EP  - AB206

Y2  - 2025/10/26

ER  -